Navigation Links
DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
Date:9/29/2008

GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6(R) Development Center, their joint venture in Cambridge, USA was recently scaled up to 250 liters by DSM Biologics scientists at their GMP facility in Groningen, The Netherlands. They successfully achieved 8 grams per liter for an IgG expressed by PER.C6(R) cells using chemically defined cell culture medium in a SUB (single-use bioreactor).

This result confirms a reliable, versatile and commercially feasible production platform to manufacture large amounts of therapeutic proteins with ease and economic affordability. Also, this latest result, using conventional fed-batch process, adds to the previous achievements of 27 grams per liter -- biomass corrected -- using DSM's XD(TM) technology, and demonstrating a reliable performance of the PER.C6(R) cell line under such production conditions.

Marco Cacciuttolo, CEO and President of PERCIVIA, comments that, "This new development further strengthens our commitment to modernize therapeutic protein manufacturing. The successful scale up of the high-titer fed-batch process means that the PER.C6(R) platform can be easily and quickly implemented into commercial facilities with no retrofit requirements. We continue to be very pleased and enthused by the ease of use, the reproducibility, and the overall robustness of the platform."

About PER.C6(R) Technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About XD(TM) techn
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
2. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
3. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
4. HYSTA Announces Dr. Qi Lu to continue on as President of HYSTA, USA
5. Wyeth Announces Increase in Common Stock Dividend
6. Telik Announces Receipt of Nasdaq Notice
7. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
8. Vermillion Announces Receipt of NASDAQ Panel Decision
9. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
10. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
11. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 05, 2015 The next implants ... received the CE mark (European) approval. The CE mark ... Trade Association (EFTA) and the European Union. Following the ... been granted to implants supplied by the Turkey-based company ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... The UPMC Center for Health Security today ... Emerging Leaders in Biosecurity Initiative (ELBI). As part of ... of biosecurity, UPMC has selected 28 US and international ... backgrounds, including biological science, medicine, policy, the military, think ... the vision and support of the Defense Threat Reduction ...
(Date:3/4/2015)... USDM Life Sciences , a ... industry, hired David Blewitt as Vice President ... Services and Solutions at USDM Life Sciences , which ... maintaining compliance with government regulations worldwide. , For ... life sciences regulatory and IS compliance professional with extensive ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
...  Stemline Therapeutics, Inc. today announced that Ivan Bergstein, MD, ... at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, ... Waldorf Astoria Hotel in New York City. ... Therapeutics, Inc. is a clinical stage biopharmaceutical company developing ...
... enters commercialization phase / Initial order of Sangui developed wound ... an initial order of Hemo2Spray, the Sangui developed wound spray, ... registered by the Mexican authorities in September this year. This ... and Sangui management is positive that an era of innovative ...
... assessing the safety and efficacy of hydroxyurea therapy in pediatric ... pre-operative transfusions for patients with SCD who undergo low- and ... Annual Meeting of the American Society of Hematology. ... by SCD, a serious disorder that causes normal red blood ...
Cached Biology Technology:Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 2Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 3Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 4Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 5Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 6Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease 7
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... BLOOMINGTON, Ind. -- The ranges of species will have to ... and 2100 because the climate will change more than 100 ... according to a newly published study by Indiana University researchers. ... that the rate of future change in suitable habitat will ...
... mole rats ( Heterocephalus glaber ) live in a ,hive, ... reproducing males. The rest of the mole rats in the ... not an easy task when you are virtually blind ... published in BioMed Central,s open access journal BMC Evolutionary ...
... become embedded in genomic DNA, which contains the complete ... for cells. It is known that ribonucleotides in DNA ... genomic instability and altered DNA metabolism, but not much ... A new study provides a mechanistic explanation of how ...
Cached Biology News:Study finds climate changes faster than species can adapt 2Study finds climate changes faster than species can adapt 3Bottom of the swimming league: Naked mole rat sperm 2Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2
Geneticin Selective Antibiotic liquid...
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
alpha N-catenin (C-19)...
... ZMD.257. Immunogen: Synthetic peptide derived from ... Connexin 36 protein This peptide sequence ... generate another Zymed polyclonal Connexin 36 antibody ... mouse Connexin 36. Reactivity: Mouse (positive ...
Biology Products: